[Research Progress of Chimeric Antigen Receptor Modified NK Cells in the Treatment of Acute Myeloid Leukemia --Review].

Chimeric Antigen Receptor (CAR) is a research hotspot in the field of cellular immunotherapy in recent years, and CAR-T cells therapy are developing rapidly in hematological malignant tumors, but their clinical application is still limited by related risks. It is particularly important to find more optimized immunoreactive cells. Natural killer (NK) cells, as key effector cells of innate immunity, can kill tumor or infected cells quickly without prior sensitization. Autologous or allogeneic NK cell infusion has become an effective cell therapy for acute myeloid leukemia (AML). CAR-NK cells combine the advantages of CAR targeting tumor specific antigens and enhancing immune cells activity with the innate antitumor function of NK cells to enhance the targeting and lytic activity of NK cells to AML primordial cells. At present, most of the CAR-NK treatments for AML are still in the stage of specific target screening and verification. This article reviews the latest research progress of CAR-NK cell therapy in the field of AML therapy.嵌合抗原受体修饰的NK细胞在急性髓系白血病治疗领域的研究进展.嵌合抗原受体(CAR)是近年来细胞免疫治疗领域研究热点，CAR-T细胞疗法在血液恶性肿瘤方面发展迅速，但其临床应用仍受相关风险限制。寻找更为优化的免疫活性细胞尤为重要。自然杀伤(NK)细胞作为固有免疫关键效应细胞，能迅速杀死肿瘤或感染细胞而无需预先致敏。自体或异体NK细胞输注已成为急性髓系白血病(AML)有效细胞疗法。CAR-NK细胞将CAR靶向肿瘤特异性抗原及增强免疫细胞活性优势与NK细胞先天抗肿瘤功能相结合，增强了NK细胞对AML原始细胞的靶向性和裂解活性。目前针对AML的CAR-NK治疗大多还处于特异性靶标筛选和验证阶段。本文就CAR-NK细胞疗法在AML治疗领域的最新研究进展作一综述。.